Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Loans - Loss Allowance: 2017-2023

Historic Loans - Loss Allowance for Autolus Therapeutics (AUTL) over the last 6 years, with Sep 2023 value amounting to $125.9 million.

  • Autolus Therapeutics' Loans - Loss Allowance rose 167.78% to $125.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $125.9 million, marking a year-over-year increase of 167.78%. This contributed to the annual value of $173.1 billion for FY2022, which is 90.38% up from last year.
  • Per Autolus Therapeutics' latest filing, its Loans - Loss Allowance stood at $125.9 million for Q3 2023, which was down 99.93% from $173.7 billion recorded in Q2 2023.
  • In the past 5 years, Autolus Therapeutics' Loans - Loss Allowance registered a high of $173.7 billion during Q2 2023, and its lowest value of $47.0 million during Q3 2022.
  • For the 3-year period, Autolus Therapeutics' Loans - Loss Allowance averaged around $88.7 billion, with its median value being $90.9 billion (2021).
  • Its Loans - Loss Allowance has fluctuated over the past 5 years, first skyrocketed by 196.29% in 2019, then slumped by 99.16% in 2022.
  • Over the past 5 years, Autolus Therapeutics' Loans - Loss Allowance (Quarterly) stood at $88.9 billion in 2019, then remained steady at $88.9 billion in 2020, then grew by 2.27% to $90.9 billion in 2021, then skyrocketed by 90.38% to $173.1 billion in 2022, then spiked by 167.78% to $125.9 million in 2023.
  • Its Loans - Loss Allowance stands at $125.9 million for Q3 2023, versus $173.7 billion for Q2 2023 and $173.1 billion for Q1 2023.